Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Trial fallito
Arpo-70 me coion😙
- Creatore Discussione Miki & Varenne
- Data di inizio
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Mi sono messo a 0,97 Oggi per poco ...1 di minimo
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Dentro 1,03 adesso
max due settimane i risultati ph2, eccitazione sui forum usa, cassa per 2 anni
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Si si conosco già il pezzo .. ne ho prese pochine a 1,03 2k non le ho volute prendere sui 0,9 sul tracollo credevo che scendeva ulteriormente poi rimbalzata..se scende sotto 1 raddoppio
per me va come minimo a 1.80/2.00 e poi fanno finanziamento per assicurarsi ben oltre 2 anni di runway cash per la ph3, è una scommessa ottima, con tutta quella cassa anche se va male, hanno cmq 21/24 mesi garantiti di sopravvivenza e il prezzo di mercato sconta già un buon margine di sicurezza
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Bene
1.26 in premarket, ottimi dati
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
CINCINNATI--(BUSINESS WIRE)--
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower intra-ocular pressure (IOP) in human subjects. The data were presented as part of Special Session, entitled “The Role of the Tie2 Pathway in Ocular Disease,” at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting on May 1 in Vancouver, British Columbia.
The data on IOP were collected from two Phase 2 clinical trials, TIME-2 and TIME-2b, that were designed to evaluate the safety and efficacy of subcutaneous AKB-9778 in patients with diabetic macular edema (TIME-2) and non-proliferative diabetic retinopathy (TIME-2b). In both studies, measurements of IOP were prospectively included as safety outcomes in the study protocols.
Data from the TIME-2 clinical trial (presented at ARVO 2018, Abstract no. 1252) showed that twice-daily, subcutaneous administration of 15 mg twice daily of AKB-9778 significantly reduced IOP in these ocular normotensive patients by -1.20 ± 0.21 mmHg compared to -0.17 ± 0.30 mmHg in patients receiving placebo (mean change from baseline ± SE; p < 0.01).
These results were confirmed in the TIME-2b clinical trial and were observed from the first visit on week 12 through the last visit on week 48 (Fig. 2). Similar to TIME-2, AKB-9778 15 mg twice daily significantly reduced IOP by -1.10±0.23 mmHg compared to +0.15±0.23 in placebo patients (mean change from baseline ± SE; p < 0.001).
Figure 2. Effects on IOP (mmHg) at different timepoints from TIME-2b (mean change from baseline ± SE)
Week 12 Week 24 Week 36 Week 48
Placebo (n=57) +0.45±0.40 +0.50±0.39 +0.62±0.52 +0.34±0.35
AKB-9778 QD (n=55) -0.56±0.38 -0.56±0.40 -0.94±0.46 -0.72±0.38
AKB-9778 BID (n=55) -0.91±0.43 -1.27±0.45 -1.48±0.47 -0.94±0.40
“Although the TIME-2 and TIME-2b studies were designed to evaluate conditions other than glaucoma and included subcutaneous administration rather than a topical ocular formulation, which is typically used for this disease, we were encouraged by the consistent IOP reductions observed in two different studies,” said Stephen Hoffman, M.D., Chief Executive Officer of Aerpio. “In addition, these results are consistent with what we observed in preclinical studies in animal models, including a study presented at this conference on April 29. We are looking forward to initiating clinical development of a topical ocular formulation of AKB-9778 in the second quarter of 2019.”
Janey Wiggs, M.D., Ph.D., Associate Chief, Ophthalmology Clinical Research; Associate Director, Howe Laboratory, Massachusetts Eye and Ear Infirmary added, “The genomic work that I presented at this symposium suggests a role for the Tie-2 pathway in the control of IOP through the conventional outflow pathway. The clinical effects of Tie-2 activation on IOP that were presented by Dr. Peters are consistent with the genomic work. These data suggest that Tie2 activation is a promising approach for the treatment of glaucoma.”
Dr. Wiggs reports receiving consulting fees from Aerpio Pharmaceuticals.
Presentation details:
Presentation Title: Schlemm’s canal, a critical outflow channel for the eye, is made up of hybrid vascular/lymphatic endothelial cells. Activation of Tie2 by inhibition of VE-PTP stimulates aqueous outflow and lowers IOP.
Session Title: The Role of the Tie2 Pathway in Ocular Disease
Session Date and Time: Wednesday, May 1, 2019 from 6:15 p.m. – 7:45 p.m. PDT
Presentation Date and Time: Wednesday, May 1, 2019 from 7:30 p.m. – 7:45 p.m. PDT
Presenter: Kevin G. Peters, M.D., Chief Scientific Officer, Aerpio Pharmaceuticals
Location: Vancouver Convention Center Room West 109/110
Abstracts and full session details can be found at The Association for Research in Vision and Ophthalmology- ARVO 2019 Annual Meeting is April 28 - May 2.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to treat ocular diseases and complications of diabetes. Tie2 is an important regulator of vascular stability and its down-regulation is found in patients with diabetes and other conditions. Down-regulation is caused by activation of two inhibitors of Tie2, VE-PTP and Ang-2. The Company’s lead compound, AKB-9778, is being investigated for its potential utility in treating diabetic nephropathy and an eyedrop formulation is in development as a potential treatment for open-angle glaucoma. For more information, please visit Aerpio Pharmaceuticals – A Biopharmaceutical Company.
Data presented during “The Role of the Tie2 Pathway in Ocular Disease” symposium at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, presented data showing the potential of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower intra-ocular pressure (IOP) in human subjects. The data were presented as part of Special Session, entitled “The Role of the Tie2 Pathway in Ocular Disease,” at The Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting on May 1 in Vancouver, British Columbia.
The data on IOP were collected from two Phase 2 clinical trials, TIME-2 and TIME-2b, that were designed to evaluate the safety and efficacy of subcutaneous AKB-9778 in patients with diabetic macular edema (TIME-2) and non-proliferative diabetic retinopathy (TIME-2b). In both studies, measurements of IOP were prospectively included as safety outcomes in the study protocols.
Data from the TIME-2 clinical trial (presented at ARVO 2018, Abstract no. 1252) showed that twice-daily, subcutaneous administration of 15 mg twice daily of AKB-9778 significantly reduced IOP in these ocular normotensive patients by -1.20 ± 0.21 mmHg compared to -0.17 ± 0.30 mmHg in patients receiving placebo (mean change from baseline ± SE; p < 0.01).
These results were confirmed in the TIME-2b clinical trial and were observed from the first visit on week 12 through the last visit on week 48 (Fig. 2). Similar to TIME-2, AKB-9778 15 mg twice daily significantly reduced IOP by -1.10±0.23 mmHg compared to +0.15±0.23 in placebo patients (mean change from baseline ± SE; p < 0.001).
Figure 2. Effects on IOP (mmHg) at different timepoints from TIME-2b (mean change from baseline ± SE)
Week 12 Week 24 Week 36 Week 48
Placebo (n=57) +0.45±0.40 +0.50±0.39 +0.62±0.52 +0.34±0.35
AKB-9778 QD (n=55) -0.56±0.38 -0.56±0.40 -0.94±0.46 -0.72±0.38
AKB-9778 BID (n=55) -0.91±0.43 -1.27±0.45 -1.48±0.47 -0.94±0.40
“Although the TIME-2 and TIME-2b studies were designed to evaluate conditions other than glaucoma and included subcutaneous administration rather than a topical ocular formulation, which is typically used for this disease, we were encouraged by the consistent IOP reductions observed in two different studies,” said Stephen Hoffman, M.D., Chief Executive Officer of Aerpio. “In addition, these results are consistent with what we observed in preclinical studies in animal models, including a study presented at this conference on April 29. We are looking forward to initiating clinical development of a topical ocular formulation of AKB-9778 in the second quarter of 2019.”
Janey Wiggs, M.D., Ph.D., Associate Chief, Ophthalmology Clinical Research; Associate Director, Howe Laboratory, Massachusetts Eye and Ear Infirmary added, “The genomic work that I presented at this symposium suggests a role for the Tie-2 pathway in the control of IOP through the conventional outflow pathway. The clinical effects of Tie-2 activation on IOP that were presented by Dr. Peters are consistent with the genomic work. These data suggest that Tie2 activation is a promising approach for the treatment of glaucoma.”
Dr. Wiggs reports receiving consulting fees from Aerpio Pharmaceuticals.
Presentation details:
Presentation Title: Schlemm’s canal, a critical outflow channel for the eye, is made up of hybrid vascular/lymphatic endothelial cells. Activation of Tie2 by inhibition of VE-PTP stimulates aqueous outflow and lowers IOP.
Session Title: The Role of the Tie2 Pathway in Ocular Disease
Session Date and Time: Wednesday, May 1, 2019 from 6:15 p.m. – 7:45 p.m. PDT
Presentation Date and Time: Wednesday, May 1, 2019 from 7:30 p.m. – 7:45 p.m. PDT
Presenter: Kevin G. Peters, M.D., Chief Scientific Officer, Aerpio Pharmaceuticals
Location: Vancouver Convention Center Room West 109/110
Abstracts and full session details can be found at The Association for Research in Vision and Ophthalmology- ARVO 2019 Annual Meeting is April 28 - May 2.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to treat ocular diseases and complications of diabetes. Tie2 is an important regulator of vascular stability and its down-regulation is found in patients with diabetes and other conditions. Down-regulation is caused by activation of two inhibitors of Tie2, VE-PTP and Ang-2. The Company’s lead compound, AKB-9778, is being investigated for its potential utility in treating diabetic nephropathy and an eyedrop formulation is in development as a potential treatment for open-angle glaucoma. For more information, please visit Aerpio Pharmaceuticals – A Biopharmaceutical Company.
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
oh finalmente oggi le sbologno ne ho un mare a 1 ne ho prese anche altre l altro ieri a 0,99
partnership pending, dentro per 2$, trattano ancora sotto la cassa,
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
porca paletta a non poter operare nel premarket azz
si sgonfia a 1,11 adesso
si sgonfia a 1,11 adessoporca paletta a non poter operare nel premarket azz
tienile chiuse nel cassetto, stanno discutendo di partnership, con la cassa che hanno e quella che riceveranno stanno bene altri 4 anni, assurda sottovalutazione
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
1,14 out e m8 s9no rimesso 1,04
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Servito 1,04 mah